IL6 and osteoarthritis: Therapeutic attenuation of IL-6 or OPN via intra-IPFP delivery of neutralizing antibodies or siRNA demonstrates preclinical efficacy in ameliorating chondrocyte dysfunction and fibro-inflammatory pathology, thus positioning targeted modulation of this axis as a tractable strategy for early osteoarthritis intervention.